
ARDT Stock Forecast & Price Target
ARDT Analyst Ratings
Bulls say
Ardent Health Inc demonstrated strong financial performance with an EBITDA of $143 million, reflecting a significant year-over-year increase of 46% and an improved margin of 9.1%, up 240 basis points. The company's admissions growth of 2.9% positioned it at the high end of its annual projection, reinforcing its operational stability, while improvements in contract labor to 3.5% of salaries and wages indicate effective cost management. Additionally, positive trends within the hospital sector, alongside the company’s strategic focus on enhancing outpatient services, suggest considerable growth opportunities that indicate Ardent is positioned to better realize its earning potential.
Bears say
Ardent Health Inc. has reported an EBITDA of $143 million for the quarter, representing a 46% year-over-year increase, yet it fell 2% short of the anticipated $146 million due to a notable contribution of $15 million to $20 million from Kansas SDPs. The company's revenue adjustments of $43 million related to its shift to the Kodiak revenue cycle management platform have led to a more conservative outlook on accounts receivable collectability, further exacerbating concerns over growth prospects. Consequently, revised EBITDA-NCI estimates for 2025 and 2026 have been lowered to $542 million and $536 million, respectively, reflecting anticipated challenges in revenue generation and a reduced growth trajectory.
This aggregate rating is based on analysts' research of Ardent Health Partners LLC and is not a guaranteed prediction by Public.com or investment advice.
ARDT Analyst Forecast & Price Prediction
Start investing in ARDT
Order type
Buy in
Order amount
Est. shares
0 shares